no scripts enabled
Medikabazaar
Cart
Brilinta 90mg Tablet 14's
Brilinta 90mg Tablet 14's: Image 1
Brilinta 90mg Tablet 14's: Image 2
Brilinta 90mg Tablet 14's: Image 3

Your Advantages

Brand Astrazeneca

Brilinta 90mg Tablet contains Ticagrelor 90mg, an antiplatelet medicine used to prevent serious cardiovascular events like heart attacks and strokes.

 

Benefits

Brilinta 90mg Tablet works by preventing blood platelets from clumping together, which helps to reduce the formation of harmful blood clots in blood vessels. This action significantly lowers the risk of cardiovascular death, heart attack, and stroke, particularly in individuals with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). It also helps to reduce the risk of stent thrombosis in patients who have undergone stenting for ACS.

 

Uses and Indications

  • To reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
  • To reduce the rate of stent thrombosis in patients who have been stented for treatment of ACS.
  • To reduce the risk of a first myocardial infarction or stroke in patients with coronary artery disease (CAD) who are at high risk for such events, including those with type 2 diabetes mellitus.
  • To reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

The Brilinta 90mg Tablet contains:

  • Ticagrelor 90mg (active ingredient).
  • Excipients: mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, talc, polyethylene glycol 400, and ferric oxide yellow.
Active Ingredient(s)Ticagrelor 90mg
Therapeutic ClassAntiplatelet
Dosage FormTablet
Release TypeImmediate Release
Storage ConditionsStore between 20°C to 25°C (68°F to 77°F)
Regulatory ApprovalPrescription Drug (Rx Only)
Licensed IndicationsReduction of cardiovascular death, MI, and stroke in ACS/MI patients; reduction of stent thrombosis in stented ACS patients; reduction of first MI/stroke in high-risk CAD patients; reduction of stroke in acute ischemic stroke/TIA patients.

Dosage and Administration

  1. Initial Treatment: For acute coronary syndrome (ACS) or acute ischemic stroke/high-risk TIA, treatment typically begins with a 180 mg loading dose (two 90 mg tablets) taken with a loading dose of aspirin (300-325 mg).
  2. Maintenance Dose: Following the loading dose, the usual maintenance dosage is 90 mg twice daily for the first year after an ACS event, in combination with a daily maintenance dose of aspirin (75-100 mg). After one year, the dose may be reduced to 60 mg twice daily, as advised by your doctor.
  3. Timing: Take Brilinta 90mg Tablet with or without food, ideally at approximately the same times each day, about 12 hours apart.
  4. Missed Dose: If a dose is missed, skip it and take the next dose at its regularly scheduled time. Do not take a double dose to make up for a missed one.
  5. Administration for Swallowing Difficulty: If you have difficulty swallowing the tablet whole, it can be crushed and mixed with a small amount of water. Drink the mixture immediately, then rinse the glass with more water and drink that as well to ensure the full dose is taken.

 

Storage and Disposal

  • Store Brilinta 90mg Tablet at room temperature, ideally between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to 30°C (59°F to 86°F).
  • Keep the container tightly closed and protect the tablets from moisture and excessive heat.
  • Keep this medicine out of the reach of children and pets.

Precautions and Safety

  • Brilinta, like other antiplatelet agents, carries a risk of bleeding, which can be significant and, in rare cases, fatal.
  • Do not use Brilinta if you have active pathological bleeding or a history of intracranial hemorrhage.
  • Avoid maintenance doses of aspirin exceeding 100 mg daily, as higher doses can reduce the effectiveness of Brilinta.
  • Do not stop taking Brilinta without consulting your prescribing doctor, as discontinuing the medication prematurely increases the risk of subsequent cardiovascular events, including heart attack and stroke.
  • Inform all healthcare providers, including doctors and dentists, that you are taking Brilinta before any medical procedures or surgeries.
  • Avoid use in patients with severe hepatic impairment due to a probable increase in exposure to ticagrelor.
  • If you are taking digoxin, your doctor may monitor digoxin levels when initiating or changing Brilinta therapy.

 

Side Effects and Risks

  • Common side effects include dyspnea (shortness of breath), increased bruising, nosebleeds, and longer bleeding time from minor injuries. Other common effects may include dizziness, nausea, diarrhea, slow heartbeat rate, and rash.
  • Seek immediate medical attention if you experience severe, uncontrollable bleeding (e.g., pink, red, or brown urine; vomit that is bloody or looks like coffee grounds; red or black stool; or coughing up blood or blood clots). Serious side effects can also include an abnormally slow heart rate, irregular breathing, or signs of a serious allergic reaction such as swelling of the face, throat, lips, tongue, hands, or feet.

 

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.

twitterlinkedinfacebookinstagramyoutube
@Copyright Boston Ivy Healthcare Solutions Private Limited